Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension

被引:29
作者
Chaumais, Marie-Camille [1 ,2 ,3 ]
Djessas, Mohamed Reda Amar [1 ,4 ]
Thuillet, Raphael [1 ,4 ]
Cumont, Amelie [1 ,4 ]
Ly Tu [1 ,4 ]
Hebert, Guillaume [5 ]
Gaignard, Pauline [2 ,6 ]
Huertas, Alice [1 ,4 ,7 ]
Savale, Laurent [1 ,4 ,7 ]
Humbert, Marc [1 ,4 ,7 ]
Guignabert, Christophe [1 ,4 ]
机构
[1] Hop Marie Lannelongue, UMR S Pulm Hypertens Pathophysiol & Novel Therapi, INSERM, F-92350 Le Plessis Robinson, France
[2] Univ Paris Saclay, Fac Pharm, F-92290 Chatenay Malabry, France
[3] Hop Bicetre, AP HP, Serv Pharm, F-94270 Le Kremlin Bicetre, France
[4] Univ Paris Saclay, Fac Med, F-94270 Le Kremlin Bicetre, France
[5] Hop Marie Lannelongue, Serv Pharm, F-92350 Le Plessis Robinson, France
[6] Hop Bicetre, AP HP, Lab Biochim, F-94270 Le Kremlin Bicetre, France
[7] Hop Bicetre, AP HP, Serv Pneumol & Soins Intensifs Resp, F-94270 Le Kremlin Bicetre, France
关键词
Pulmonary arterial hypertension; Pulmonary vascular remodelling; Cardiac dysfunction; Entresto; HEART-FAILURE; INHIBITION; RATS;
D O I
10.1093/cvr/cvaa200
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Although right ventricular (RV) function is an important determinant of morbidity and mortality in patients with pulmonary arterial hypertension (PAH), there is no treatment targeting directly the RV. We evaluate the efficacy of sacubitril/valsartan (LCZ 696) as add-on therapy to bosentan in rats with severe pulmonary hypertension (PH). Methods and results Combination therapy of LCZ 696 and bosentan has additive vascular protective effects against the pulmonary vascular remodelling and PH in two preclinical models of severe PH. Compared with monotherapy, co-treatment of LCZ 696 (30 or 68 mg/kg/day for 2 weeks, per os) and bosentan (100 mg/kg/day for 2 weeks, per os) started 7 days after monocrotaline (MCT) injection substantially reduces pulmonary pressures, vascular remodelling, and RV hypertrophy and fibrosis in rats. Consistent with these observations, co-treatment of rats with established PH induced by sugen/hypoxia (SuHx) with LCZ 696 (30 mg/kg/day for 3 weeks, per os) and bosentan (100 mg/kg/day for 3 weeks, per os) started 5 weeks after Sugen injection partially attenuate total pulmonary vascular resistance and cardiovascular structures. We also obtained evidence showing that LCZ 696 has anti-proliferative effect on cultured human pulmonary artery smooth muscle cells derived from patients with idiopathic PAH, an effect that is more pronounced in presence of bosentan. Finally, we found that the plasma levels of atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) are higher in rats co-treated with LCZ 696 (30 mg/kg/day) and bosentan (100 mg/kg/day) than in MCT and SuHx rats treated with vehicle. Conclusion Dual therapy with LCZ 696 plus bosentan proved significantly superior beneficial effect to LCZ 696 or bosentan alone on vascular remodelling and severity of experimental PH. [GRAPHICS] .
引用
收藏
页码:1391 / 1401
页数:11
相关论文
共 36 条
[1]   Dual endothelin receptor antagonism with bosentan reverses established vascular remodeling and dysfunctional angiogenesis in diabetic rats: Relevance to glycemic control [J].
Abdelsaid, Mohammed ;
Kaczmarek, Jessica ;
Coucha, Maha ;
Ergul, Adviye .
LIFE SCIENCES, 2014, 118 (02) :268-273
[2]   Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension [J].
Aiello, Robert J. ;
Bourassa, Patricia-Ann ;
Zhang, Qing ;
Dubins, Jeffrey ;
Goldberg, Daniel R. ;
De Lombaert, Stephane ;
Humbert, Marc ;
Guignabert, Christophe ;
Cavasin, Maria A. ;
McKinsey, Timothy A. ;
Paralkar, Vishwas .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2017, 360 (02) :267-279
[3]   Effects of combined angiotensin II receptor antagonism and neprilysin inhibition in experimental pulmonary hypertension and right ventricular failure [J].
Andersen, Stine ;
Axelsen, Julie Birkmose ;
Ringgaard, Steffen ;
Nyengaard, Jens Randel ;
Hyldebrandt, Janus Adler ;
Bogaard, Harm Jan ;
de Man, Frances S. ;
Nielsen-Kudsk, Jens Erik ;
Andersen, Asger .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 293 :203-210
[4]   Optimising experimental research in respiratory diseases: an ERS statement [J].
Bonniaud, Philippe ;
Fabre, Aurelie ;
Frossard, Nelly ;
Guignabert, Christophe ;
Inman, Mark ;
Kuebler, Wolfgang M. ;
Maes, Tania ;
Shi, Wei ;
Stampfli, Martin ;
Uhlig, Stefan ;
White, Eric ;
Witzenrath, Martin ;
Bellaye, Pierre-Simon ;
Crestani, Bruno ;
Eickelberg, Oliver ;
Fehrenbach, Heinz ;
Guenther, Andreas ;
Jenkins, Gisli ;
Joos, Guy ;
Magnan, Antoine ;
Maitre, Bernard ;
Maus, Ulrich A. ;
Reinhold, Petra ;
Vernooy, Juanita H. J. ;
Richeldi, Luca ;
Kolb, Martin .
EUROPEAN RESPIRATORY JOURNAL, 2018, 51 (05)
[5]   Neutralization of CXCL12 attenuates established pulmonary hypertension in rats [J].
Bordenave, Jennifer ;
Thuillet, Raphael ;
Tu, Ly ;
Phan, Carole ;
Cumont, Amelie ;
Marsol, Claire ;
Huertas, Alice ;
Savale, Laurent ;
Hibert, Marcel ;
Galzi, Jean-Luc ;
Bonnet, Dominique ;
Humbert, Marc ;
Frossard, Nelly ;
Guignabert, Christophe .
CARDIOVASCULAR RESEARCH, 2020, 116 (03) :686-697
[6]  
Casserly B, 2009, DRUG DES DEV THER, V3, P269
[7]   Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension [J].
Chaumais, Marie-Camille ;
Guignabert, Christophe ;
Savale, Laurent ;
Jais, Xavier ;
Boucly, Athenais ;
Montani, David ;
Simonneau, Grald ;
Humbert, Marc ;
Sitbon, Olivier .
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2015, 15 (01) :13-26
[8]   Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan [J].
Clements, Richard T. ;
Vang, Alexander ;
Fernandez-Nicolas, Ana ;
Kue, Nouaying R. ;
Mancini, Thomas J. ;
Morrison, Alan R. ;
Mallem, Krishna ;
McCullough, Danielle J. ;
Choudhary, Gaurav .
CIRCULATION-HEART FAILURE, 2019, 12 (11)
[9]  
De Simone Vincenzo, 2019, J Cardiol Cases, V20, P187, DOI 10.1016/j.jccase.2019.08.006
[10]   Neprilysin Null Mice Develop Exaggerated Pulmonary Vascular Remodeling in Response to Chronic Hypoxia [J].
Dempsey, Edward C. ;
Wick, Marilee J. ;
Karoor, Vijaya ;
Barr, Erica J. ;
Tallman, Dustin W. ;
Wehling, Carol A. ;
Walchak, Sandra J. ;
Laudi, Sven ;
Le, Mysan ;
Oka, Masahiko ;
Majka, Susan ;
Cool, Carlyne D. ;
Fagan, Karen A. ;
Klemm, Dwight J. ;
Hersh, Louis B. ;
Gerard, Norma P. ;
Gerard, Craig ;
Miller, York E. .
AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (03) :782-796